FLT1 and renal cell carcinoma: Sunitinib targets VEGFR-1/2/3, PDGFR, c-Kit receptor, fms-like tyrosine kinase-3 receptor (FLT-3), and receptor encoded by the ret proto-oncogene (Ret) and is approved for treatment drug-resistant gastrointestinal stromal tumours (GIST) and RCC (151–154).